GeneDx (NASDAQ:WGS – Get Free Report) is scheduled to be releasing its earnings data before the market opens on Tuesday, October 29th. Analysts expect GeneDx to post earnings of ($0.19) per share for the quarter. GeneDx has set its FY 2024 guidance at EPS.Individual interested in registering for the company’s earnings conference call can do so using this link.
GeneDx (NASDAQ:WGS – Get Free Report) last announced its quarterly earnings data on Tuesday, July 30th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.15. The business had revenue of $70.51 million during the quarter, compared to analyst estimates of $58.90 million. GeneDx had a negative return on equity of 22.71% and a negative net margin of 48.21%. On average, analysts expect GeneDx to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
GeneDx Stock Down 3.1 %
Shares of GeneDx stock opened at $58.19 on Tuesday. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.38 and a quick ratio of 2.22. The company has a 50-day moving average of $41.34 and a 200 day moving average of $29.89. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -11.23 and a beta of 2.32. GeneDx has a 1 year low of $1.16 and a 1 year high of $61.96.
Insider Activity at GeneDx
Analysts Set New Price Targets
WGS has been the topic of a number of analyst reports. BTIG Research boosted their price target on GeneDx from $35.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Wells Fargo & Company initiated coverage on GeneDx in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $34.00 target price on the stock. Craig Hallum lifted their price target on GeneDx from $43.00 to $46.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. The Goldman Sachs Group upped their price target on shares of GeneDx from $32.00 to $54.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 16th. Finally, TD Cowen raised their price objective on shares of GeneDx from $46.00 to $50.00 and gave the company a “buy” rating in a research note on Wednesday, July 31st. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, GeneDx presently has an average rating of “Moderate Buy” and an average price target of $41.67.
View Our Latest Stock Report on WGS
GeneDx Company Profile
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Read More
- Five stocks we like better than GeneDx
- Why Invest in 5G? How to Invest in 5G Stocks
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- Trading Stocks: RSI and Why it’s Useful
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- What is Put Option Volume?
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.